Assenagon Asset Management S.A. Cuts Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Assenagon Asset Management S.A. lessened its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 30.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 331,758 shares of the biotechnology company’s stock after selling 143,688 shares during the quarter. Assenagon Asset Management S.A. owned 1.09% of AnaptysBio worth $4,392,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Values First Advisors Inc. purchased a new position in shares of AnaptysBio in the 3rd quarter valued at about $49,000. nVerses Capital LLC increased its holdings in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares in the last quarter. Point72 DIFC Ltd increased its holdings in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of AnaptysBio in the 3rd quarter valued at about $229,000.

AnaptysBio Price Performance

AnaptysBio stock opened at $15.85 on Tuesday. AnaptysBio, Inc. has a 12-month low of $12.51 and a 12-month high of $41.31. The stock has a market capitalization of $482.30 million, a P/E ratio of -2.61 and a beta of -0.02. The firm’s 50-day moving average is $17.96 and its two-hundred day moving average is $27.79.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of research analyst reports. Guggenheim cut their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Wedbush reissued an “outperform” rating and issued a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average target price of $41.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.